{"id":15469,"date":"2026-02-11T09:28:35","date_gmt":"2026-02-11T09:28:35","guid":{"rendered":"https:\/\/jobuzo.com\/en\/capital-injection-china-backs-ai-drug-makers-in-self-reliance-drive\/"},"modified":"2026-02-11T09:28:35","modified_gmt":"2026-02-11T09:28:35","slug":"capital-injection-china-backs-ai-drug-makers-in-self-reliance-drive","status":"publish","type":"post","link":"https:\/\/jobuzo.com\/en\/capital-injection-china-backs-ai-drug-makers-in-self-reliance-drive\/","title":{"rendered":"Capital injection: China backs AI drug makers in self-reliance drive"},"content":{"rendered":"
\n
<\/div>\n

Hangzhou-based METiS TechBio, founded in 2020, raised 400 million yuan (US$57.9 million) in series D financing in August last year, led by the Beijing Medical and Health Industry Investment Fund and the Daxing Industrial Investment Fund – both government-linked vehicles – according to the company’s website.<\/p>\n

Using a proprietary AI platform focused on optimising drug delivery, the company has developed MTS-004, an oral treatment for neurological disorders that has completed Phase III trials, making it China’s first AI-designed drug candidate to reach that stage.<\/p>\n

\n
\n

Advertisement<\/p>\n<\/div>\n<\/div>\n

The company plans to seek regulatory approval in China this year.<\/p>\n

In earlier funding rounds totalling about US$150 million in 2022, METiS attracted a broad mix of domestic investors, including state-linked insurers PICC Capital and China Life Private Equity, as well as venture firm HongShan, formerly known as Sequoia China before splitting from its US parent in 2023.<\/p>\n

\n
\n

Advertisement<\/p>\n<\/div>\n<\/div>\n

News :<\/span><div>12 weeks' jail for school IT support technician who took upskirt videos of teachers<\/div><\/span><\/a><\/div>

METiS is also considering a Hong Kong initial public offering that could raise about US$200 million, according to a Bloomberg report published last May.<\/p>\n<\/div>\n

Capital injection: China backs AI drug makers in self-reliance drive<\/sub><\/p>\n","protected":false},"excerpt":{"rendered":"

Hangzhou-based METiS TechBio, founded in 2020, raised 400 million yuan (US$57.9 million) in series D financing in August last year, led by the Beijing Medical and Health Industry Investment Fund and the Daxing Industrial Investment Fund – both government-linked vehicles – according to the company’s website. Using a proprietary AI platform focused on optimising drug…<\/p>\n

Read More “Capital injection: China backs AI drug makers in self-reliance drive”<\/span> »<\/a><\/p>\n","protected":false},"author":1,"featured_media":15470,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-15469","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/jobuzo.com\/en\/wp-json\/wp\/v2\/posts\/15469","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jobuzo.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jobuzo.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jobuzo.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jobuzo.com\/en\/wp-json\/wp\/v2\/comments?post=15469"}],"version-history":[{"count":0,"href":"https:\/\/jobuzo.com\/en\/wp-json\/wp\/v2\/posts\/15469\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/jobuzo.com\/en\/wp-json\/wp\/v2\/media\/15470"}],"wp:attachment":[{"href":"https:\/\/jobuzo.com\/en\/wp-json\/wp\/v2\/media?parent=15469"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jobuzo.com\/en\/wp-json\/wp\/v2\/categories?post=15469"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jobuzo.com\/en\/wp-json\/wp\/v2\/tags?post=15469"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}